PS: the Futility assessment is the proxy here for P2B success / progress.
Mid 2023 is the 'Futility Analysis' - at this stage the researchers (Prof Voit) determines if there is statistical improvement vs control...we either continue...or...not.
How do we think the market will react if we tick the box at Futility Assessment?
That is 19 months away!
As Diamond said in the presser this morning:
"With only a small number of ASX listed companies having made the journey into Phase III clinical development we know that we are in rarified pharmaceutical company. We appreciate the challenges that may lay ahead, though our highly experienced board and management team are very excited and energized to be embarking on this final stage of clinical development...."
A bit of theatre here folks - love it!
.
Ann: Positive PDCO opinion and A$20m Placement, page-72
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
